Fennec Pharmaceuticals Reports Strong Q1 2026 Performance with Revenue Growth of 73% Year-Over-Year
Fennec Pharmaceuticals Inc. reported a significant year-over-year revenue increase driven by the 'Project Ignite' initiative and expanded sales reach, targeting over 5,000 prescribers in the Adolescent and Young Adult (AYA) market. The company also highlighted improvements in its patient support program and strategic partnerships to integrate PEDMARK into electronic medical records.
Tickers: $NVDA
Topics: Pharmaceuticals Product Adoption Revenue Growth Sales Strategy